Abstract
Purpose: Hypertension (HTN) is considered a major health problem. Apelin (AP) a novel multifunction peptide implicated in regulation of the cardiovascular system, including blood pressure and cardiac function control, Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions. However, there is no data about ADMA and apelin levels in essential hypertension and any relationship between them and the effect of antihypertensive drugs from various classes on these parameters of endothelial function. The aim of this study is to assess the status of Apelin and Assymetric DiMethyl Arginine in essential Hypertension on various modalities of treatment. Methods: The present study is a cross-sectional study (2007/2008) at Al-Yarmouk Teaching Hospital. Includes measurement of serum AP and ADMA in patients with hypertension. a total of 80 patients with HTN were involved in this study, they were classified according to modality of treatment as Hypertensives on captopril G1: (n=40); Hypertensives on atenolol G2: (n=40). A matching group of eighty apparently healthy volunteers who were included as controls (n=80. Results: Serum AP was significantly reduced and serum ADMA was significantly elevated in hypertensive patients (G1 & G2) as compared with controls (G3) (p < 0.001), also the above significant alteration in these two parameters was found when hypertensives on atenolol (G2) were compared with hypertensives on captopril (G1) (p < 0.001). AP was negatively correlated with ADMA (r = -0.9, p
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
